Heart Failure with preserved ejection fraction: a pharmacotherapeutic update

Dados básicos

Código:
Estudo Clínico Académico
Protocolo:
Estudo Clínico Académico
EUDRACT:
NCT:
Centro:
Dotação:
Ano de início:
2022
Ano de conclusão:
Estudos observacionais Nacional Não Financiado Outros

Objectivos do projeto

Estudos Observacionais (STROBE statement); Natureza do Promotor: Academia – Tipo não comercial – Iniciativa do Investigador; Tipo de Centro: Unicêntrico – Cuidados Secundários

Documentos

  • Não há documentos

Participantes

Unidades de investigação

Stakeholders - Promotores

FMUP

Outputs do ensaio clínico


Candidate microRNAs as prognostic biomarkers in heart failure: A systematic review

Figueiredo, R; (...); Brás-Silva, C

Review. 10.1016/j.repc.2021.03.020. 2022

  • Open Access.

Editorial: Therapeutics in pulmonary arterial hypertension

Adao, Rui; (...); Bras-Silva, Carmen

Editorial Material. 10.3389/fcvm.2024.1463305. 2024

  • Open Access.

Emerging Roles of Micrornas in Veterinary Cardiology

Reis-Ferreira, A; (...); Fontes-Sousa, AP

Review. 10.3390/vetsci9100533. 2022

  • Open Access.

NTP42 alleviates experimental pulmonary arterial hypertension and promotes beneficial right ventricular adaptation, preserving right heart function

Mulvaney, E.; (...); Kinsella, B. T.

Meeting Abstract. 10.1183/13993003.congress-2022.1195. 2022


Pathophysiological and therapeutic implications of urocortin-2 in heart failure with preserved ejection fraction

Adao, R; (...); Bras-Silva, C

Meeting Abstract. 2022


Physiological and pathophysiological roles of the KCNK3 potassium channel in the pulmonary circulation and the heart

Willer, ASM; (...); Antigny, F

Review. 10.1113/JP284936. 2023

  • Open Access.

Pulmonary Valve Replacement: A New Paradigm with Tissue Engineering

Almeida-Pintoa, R; (...); Adao, R

Review. 10.1016/j.cpcardiol.2022.101212. 2023

  • Open Access.

The Ketone Bridge Between the Heart and the Bladder: How Fast Should We Go?

Faria-Costa, Gabriel; (...); Charrua, Ana

Article. 10.5213/inj.2346250.125. 2024

  • Open Access.

The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload

Mulvaney, EP; (...); Kinsella, BT

Article. 10.3389/fcvm.2022.1063967. 2022

  • Open Access.

Therapeutic Approaches in Pulmonary Arterial Hypertension with Beneficial Effects on Right Ventricular Function-Preclinical Studies

Balsa, A, Adao, R, Brás-Silva, C

Review. 10.3390/ijms242115539. 2023

  • Open Access.

Therapeutic effects of nebulization-based delivery of anti-miR-146a in experimental pulmonary arterial hypertension

Santos Peixoto Gomes, J.; (...); Bras-Silva, C.

Meeting Abstract. 2022


Urocortin-2 as a novel biomarker of clinical deterioration in HFpEF: a prospective cohort study

Ines Vasconcelos, I.; (...); Bras-Silva, C.

Meeting Abstract. 2024


An Overview Of Circulating Pulmonary Arterial Hypertension Biomarkers

Trabalho final de curso

Colaboradores: Carmen Dulce da Silveira Brás Silva Ribeiro


An Overview Of Circulating Pulmonary Arterial Hypertension Biomarkers

Dissertação de Mestrado

Colaboradores: Carmen Dulce da Silveira Brás Silva Ribeiro


Heart Failure With Preserved Ejection Fraction: A Pharmacotherapeutic Update

Trabalho final de curso

Colaboradores: Carmen Dulce da Silveira Brás Silva Ribeiro


Heart Failure With Preserved Ejection Fraction: A Pharmacotherapeutic Update

Dissertação de Mestrado

Colaboradores: Carmen Dulce da Silveira Brás Silva Ribeiro


Therapeutic Aproaches In Pah With Beneficial Effects On Right Ventricular Function - Preclinical Studies

Trabalho final de curso

Colaboradores: Carmen Dulce da Silveira Brás Silva Ribeiro


Partilhar